论文部分内容阅读
应用增殖细胞核抗原(PCNA)抗体的免疫金银法的免疫组织化学技术,检测了52例肝细胞癌,12例肝细胞异型性增生和35例肝硬变组织内细胞核PCNA的活性,20例正常肝组织作对照。结果表明,52例肝细胞癌PCNA的总阳性率为84.6％。Ⅰ级16例、Ⅱ级22例、Ⅲ级10例和Ⅳ级4例,各级的阳性率分别为93.35％、86.4％、80％和50％;视为肝癌前病变的肝细胞异型增生12例,其阳性率为91.7％,提示PCNA抗体的免疫组化检测可作为一项新的肝细胞癌早期诊断的指标;并说明肝细胞癌分化程度越高。PCNA检出阳性率越高,呈正相关。
Immunohistochemical technique of immunogold-silver assay using proliferating cell nuclear antigen (PCNA) antibody detected 52 cases of hepatocellular carcinoma, 12 cases of hepatocyte dysplasia and 35 cases of cirrhosis tissue PCNA activity, 20 cases of normal liver tissue For comparison. The results showed that the total positive rate of PCNA in 52 cases of hepatocellular carcinoma was 84.6%. There were 16 patients with grade I, 22 patients with grade II, 10 patients with grade III and 4 patients with grade IV. The positive rates at all levels were 93.35%, 86.4%, 80%, and 50%, respectively; hepatocyte dysplasia seen as an anterior lesion of liver cancer 12 For example, the positive rate was 91.7%, suggesting that immunohistochemical detection of PCNA antibody can be used as a new indicator for the early diagnosis of hepatocellular carcinoma; and the higher the degree of differentiation of hepatocellular carcinoma is. The higher the positive rate of PCNA detection, the positive correlation.